Progyny: 3 Key Takeaways for Long-Term Investors

Progyny reported record results for its 2026 selling season, adding 1.3 million covered lives across 85+ new clients, bringing total coverage to 8.3 million for 2027. The company benefits from competitor exits and restructuring, strengthening its market position. Management raised full-year guidance and has repurchased over 14 million shares since November 2025, demonstrating strong cash generation and shareholder returns.